[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN113906051A - 对cd73具有特异性的结合分子及其用途 - Google Patents

对cd73具有特异性的结合分子及其用途 Download PDF

Info

Publication number
CN113906051A
CN113906051A CN202080040794.8A CN202080040794A CN113906051A CN 113906051 A CN113906051 A CN 113906051A CN 202080040794 A CN202080040794 A CN 202080040794A CN 113906051 A CN113906051 A CN 113906051A
Authority
CN
China
Prior art keywords
seq
acid sequence
nucleic acid
amino acid
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080040794.8A
Other languages
English (en)
Inventor
刘庆浩
周文来
杨海艳
王红玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jacobio Pharmaceuticals Co Ltd
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of CN113906051A publication Critical patent/CN113906051A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明提供对CD73具有特异性的结合分子及其用途，具体而言，本发明提供结合CD73且抑制CD73活性的分离的抗体或其抗原结合部分。本发明亦提供本发明分离的抗体或其抗原结合部分在治疗疾病中的用途。本发明亦提供编码本发明分离的抗体或其抗原结合部分的核酸分子，用于表达本发明分离的抗体或其抗原结合部分的表达载体、宿主细胞及制备方法。

Description

PCT国内申请，说明书已公开。

Claims (71)

  1. PCT国内申请，权利要求书已公开。
CN202080040794.8A 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途 Pending CN113906051A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019090366 2019-06-06
CNPCT/CN2019/090366 2019-06-06
PCT/CN2020/094489 WO2020244606A1 (zh) 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途

Publications (1)

Publication Number Publication Date
CN113906051A true CN113906051A (zh) 2022-01-07

Family

ID=73653110

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040794.8A Pending CN113906051A (zh) 2019-06-06 2020-06-05 对cd73具有特异性的结合分子及其用途

Country Status (12)

Country Link
US (2) US11174319B2 (zh)
EP (1) EP3981790A4 (zh)
JP (1) JP2022535840A (zh)
KR (1) KR20220016974A (zh)
CN (1) CN113906051A (zh)
AU (1) AU2020289179B2 (zh)
BR (1) BR112021024553A2 (zh)
CA (1) CA3142640A1 (zh)
EA (1) EA202193351A1 (zh)
MX (1) MX2021014952A (zh)
TW (1) TWI790445B (zh)
WO (1) WO2020244606A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032777A1 (zh) * 2022-08-12 2024-02-15 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024217447A1 (zh) * 2023-04-17 2024-10-24 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023509448A (ja) 2020-01-03 2023-03-08 インサイト・コーポレイション 抗ｃｄ７３抗体及びその使用
CN115551595A (zh) 2020-01-03 2022-12-30 因赛特公司 Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024138910A1 (en) * 2022-12-26 2024-07-04 Bliss Biopharmaceutical (Hangzhou) Co., Ltd. Anti-cd73 antibody and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
WO2016081748A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6670297B2 (ja) * 2014-08-07 2020-03-18 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体
PT3204417T (pt) * 2014-10-10 2020-10-08 Innate Pharma Bloqueio de cd73
JP7391510B2 (ja) * 2015-12-09 2023-12-05 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
NZ753714A (en) * 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. TREATMENT METHODS FOR HIGH CD73 TUMORS
MX2019015885A (es) * 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370830A (zh) * 2005-09-26 2009-02-18 米德列斯公司 抗cd70的人单克隆抗体
WO2016081748A2 (en) * 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
CN107001474A (zh) * 2014-11-21 2017-08-01 百时美施贵宝公司 抗cd73抗体及其用途
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032777A1 (zh) * 2022-08-12 2024-02-15 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024217447A1 (zh) * 2023-04-17 2024-10-24 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用

Also Published As

Publication number Publication date
WO2020244606A1 (zh) 2020-12-10
JP2022535840A (ja) 2022-08-10
US20220064322A1 (en) 2022-03-03
CA3142640A1 (en) 2020-12-10
EP3981790A4 (en) 2023-10-11
BR112021024553A2 (pt) 2022-05-24
TWI790445B (zh) 2023-01-21
AU2020289179B2 (en) 2024-05-02
TW202112814A (zh) 2021-04-01
EA202193351A1 (ru) 2022-03-21
US11174319B2 (en) 2021-11-16
MX2021014952A (es) 2022-04-06
AU2020289179A1 (en) 2021-11-18
KR20220016974A (ko) 2022-02-10
EP3981790A1 (en) 2022-04-13
US20210253730A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
JP7271637B2 (ja) 抗ｐｓｍａ抗体、ｐｓｍａ及びｃｄ３と結合する二重特異性抗原結合分子、ならびにその使用
TWI790445B (zh) 對cd73具有特異性的結合分子及其用途
JP2023154021A (ja) 最適化抗ｃｄ３二重特異性抗体及びその使用
JP7461741B2 (ja) 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
WO2020098734A1 (zh) 抗tigit抗体及其用途
CN108738324B (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途
US20230192840A1 (en) Antibody and use thereof
US20200131267A1 (en) Antibodies
WO2021088838A1 (zh) 对cd39具有特异性的结合分子及其用途
TWI793395B (zh) 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
KR20230012000A (ko) 항체 약물 컨쥬게이트, 이의 제조 방법 및 이의 용도
EP4292611A1 (en) Anti-cd112r antibody and use thereof
JP7290568B2 (ja) 癌免疫療法のための併用療法での多重特異性抗体
TW202144429A (zh) 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
WO2023078386A1 (zh) 抗cldn18.2抗体及其用途
US20210403582A1 (en) Binding molecule specific for lif and use thereof
WO2023186100A1 (zh) 抗ror1的抗体及其用途
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
CN117510641A (zh) 靶向cd112r和tigit的双特异性抗体及其用途
KR20240053586A (ko) 항il4r 항체의 의약 조성물 및 그의 사용

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063856

Country of ref document: HK